Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

Sewon Kang, Anne W. Lucky, David Pariser, Ira Lawrence, Jon Hanifin

Research output: Contribution to journalArticle

294 Citations (Scopus)

Abstract

Tacrolimus ointment is a nonsteroidal topical immunomodulator that was formulated specifically for the treatment of atopic dermatitis. A total of 255 children, 2 to 15 years of age, with moderate to severe atopic dermatitis applied 0.1% tacrolimus ointment twice daily for up to 12 months to assess long-term safety and efficacy. Patients on average were treated with tacrolimus ointment for 279 days or 87% of study days. Substantial improvements in the signs and symptoms of atopic dermatitis, percent body surface area affected, and the patient's or parent's assessment of pruritus were observed during the first week of treatment and were maintained throughout the study. Transient skin burning and itching were the most common drug application site adverse events. Occurrence of these symptoms decreased after the first few days of treatment. There was no increased incidence of infections or other significant adverse events. Effectiveness of tacrolimus was maintained with prolonged daily use. Tacrolimus ointment (0.1%) is safe and effective for long-term treatment of atopic dermatitis in children.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
Volume44
Issue number1 SUPPL.
DOIs
StatePublished - 2001

Fingerprint

Tacrolimus
Atopic Dermatitis
Ointments
Safety
Pruritus
Therapeutics
Body Surface Area
Immunologic Factors
Signs and Symptoms
Parents
Skin
Incidence
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. / Kang, Sewon; Lucky, Anne W.; Pariser, David; Lawrence, Ira; Hanifin, Jon.

In: Journal of the American Academy of Dermatology, Vol. 44, No. 1 SUPPL., 2001.

Research output: Contribution to journalArticle

@article{dd263eb3d6ce4074853b59c522b06cf9,
title = "Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children",
abstract = "Tacrolimus ointment is a nonsteroidal topical immunomodulator that was formulated specifically for the treatment of atopic dermatitis. A total of 255 children, 2 to 15 years of age, with moderate to severe atopic dermatitis applied 0.1{\%} tacrolimus ointment twice daily for up to 12 months to assess long-term safety and efficacy. Patients on average were treated with tacrolimus ointment for 279 days or 87{\%} of study days. Substantial improvements in the signs and symptoms of atopic dermatitis, percent body surface area affected, and the patient's or parent's assessment of pruritus were observed during the first week of treatment and were maintained throughout the study. Transient skin burning and itching were the most common drug application site adverse events. Occurrence of these symptoms decreased after the first few days of treatment. There was no increased incidence of infections or other significant adverse events. Effectiveness of tacrolimus was maintained with prolonged daily use. Tacrolimus ointment (0.1{\%}) is safe and effective for long-term treatment of atopic dermatitis in children.",
author = "Sewon Kang and Lucky, {Anne W.} and David Pariser and Ira Lawrence and Jon Hanifin",
year = "2001",
doi = "10.1067/mjd.2001.109812",
language = "English (US)",
volume = "44",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

AU - Kang, Sewon

AU - Lucky, Anne W.

AU - Pariser, David

AU - Lawrence, Ira

AU - Hanifin, Jon

PY - 2001

Y1 - 2001

N2 - Tacrolimus ointment is a nonsteroidal topical immunomodulator that was formulated specifically for the treatment of atopic dermatitis. A total of 255 children, 2 to 15 years of age, with moderate to severe atopic dermatitis applied 0.1% tacrolimus ointment twice daily for up to 12 months to assess long-term safety and efficacy. Patients on average were treated with tacrolimus ointment for 279 days or 87% of study days. Substantial improvements in the signs and symptoms of atopic dermatitis, percent body surface area affected, and the patient's or parent's assessment of pruritus were observed during the first week of treatment and were maintained throughout the study. Transient skin burning and itching were the most common drug application site adverse events. Occurrence of these symptoms decreased after the first few days of treatment. There was no increased incidence of infections or other significant adverse events. Effectiveness of tacrolimus was maintained with prolonged daily use. Tacrolimus ointment (0.1%) is safe and effective for long-term treatment of atopic dermatitis in children.

AB - Tacrolimus ointment is a nonsteroidal topical immunomodulator that was formulated specifically for the treatment of atopic dermatitis. A total of 255 children, 2 to 15 years of age, with moderate to severe atopic dermatitis applied 0.1% tacrolimus ointment twice daily for up to 12 months to assess long-term safety and efficacy. Patients on average were treated with tacrolimus ointment for 279 days or 87% of study days. Substantial improvements in the signs and symptoms of atopic dermatitis, percent body surface area affected, and the patient's or parent's assessment of pruritus were observed during the first week of treatment and were maintained throughout the study. Transient skin burning and itching were the most common drug application site adverse events. Occurrence of these symptoms decreased after the first few days of treatment. There was no increased incidence of infections or other significant adverse events. Effectiveness of tacrolimus was maintained with prolonged daily use. Tacrolimus ointment (0.1%) is safe and effective for long-term treatment of atopic dermatitis in children.

UR - http://www.scopus.com/inward/record.url?scp=0035157388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035157388&partnerID=8YFLogxK

U2 - 10.1067/mjd.2001.109812

DO - 10.1067/mjd.2001.109812

M3 - Article

C2 - 11145796

AN - SCOPUS:0035157388

VL - 44

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 1 SUPPL.

ER -